NSABP FB-10 Phase 1B


A Phase 1B/II Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DMI) with Neratinib in Women with Metastatic HER2-Positive Breast Cancer

Protocol Chair: Jame Abraham, MD

Protocol Officer: Shannon Puhalla, MD

Patient Population:
Patients with metastatic HER2-positive breast cancer

Target Accrual: 41 patients

Status: Closed

ClinicialTrials.gov Identifier: NCT02236000